Rm. Mackie et al., PROGNOSTIC MODELS FOR SUBGROUPS OF MELANOMA PATIENTS FROM THE SCOTTISH-MELANOMA-GROUP DATABASE 1979-86, AND THEIR SUBSEQUENT VALIDATION, British Journal of Cancer, 71(1), 1995, pp. 173-176
For the past 20 years thickness of the primary tumour has been accepte
d as the most important guide to prognosis for patients with primary c
utaneous malignant melanoma. The changing epidemiology of melanoma wit
h an increasing number of patients with thin tumours has necessitated
a reappraisal of this, with particular reference to interactions among
tumour thickness, the patients' sex and the presence or absence of ul
ceration of the primary tumour. All primary cutaneous malignant melano
mas diagnosed in Scotland between 1979 and 1986 were used as the test
group (1978 patients). The proportional hazards model was used on all
potential risk factors in the database and their two-way interactions,
and the resulting models based on stepwise procedures were subsequent
ly validated on 289 melanoma patients first diagnosed in 1987 in the s
ame geographic area. Four distinct subgroups of males and females with
ulcerated or non-ulcerated lesions were identified. For females with
ulcerated lesions, tumour thickness, mitotic count and anatomical site
of primary all gave valuable prognostic information, whereas for fema
les with non-ulcerated lesions only tumour thickness was of prognostic
value. For males with ulcerated lesions, level of invasion was the on
ly prognostic guide, while for males with non-ulcerated lesions both t
umour thickness and level of invasion contributed significantly to pre
diction of prognosis. Prognosis is markedly different across subgroups
of the melanoma population, even to the extent that essential prognos
tic factors are not the same in the distinct subgroups. Verification o
f these prognostic guides derived from 1979-86 patients has been achie
ved for all patients diagnosed with melanoma in 1987 from the same geo
graphic area. These data will therefore be useful aids for clinicians
managing patients.